Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Zevra Therapeutics (ZVRA) over the last 10 years, with Q3 2025 value amounting to 0.37%.

  • Zevra Therapeutics' Return on Capital Employed rose 2800.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37%, marking a year-over-year increase of 2800.0%. This contributed to the annual value of 0.62% for FY2024, which is 900.0% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Return on Capital Employed stood at 0.37%, which was up 2800.0% from 0.64% recorded in Q2 2025.
  • Zevra Therapeutics' Return on Capital Employed's 5-year high stood at 0.11% during Q1 2021, with a 5-year trough of 0.65% in Q3 2024.
  • Its 5-year average for Return on Capital Employed is 0.34%, with a median of 0.4% in 2022.
  • In the last 5 years, Zevra Therapeutics' Return on Capital Employed surged by 15900bps in 2021 and then plummeted by -5600bps in 2023.
  • Over the past 5 years, Zevra Therapeutics' Return on Capital Employed (Quarter) stood at 0.06% in 2021, then crashed by -783bps to 0.4% in 2022, then tumbled by -50bps to 0.61% in 2023, then grew by 5bps to 0.58% in 2024, then surged by 36bps to 0.37% in 2025.
  • Its last three reported values are 0.37% in Q3 2025, 0.64% for Q2 2025, and 0.48% during Q1 2025.